Glenmede Trust’s EnteroMedics Inc. ETRM Stock Holding History

Glenmede Trust’s Portfolio ETRM Stock Details ETRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2	Closed	–	–	3024
2017 Q2	$0	Hold	2	–	–	﹤0.01%	2768
2017 Q1	$0	Buy	+2	New	+$15	﹤0.01%	2887

Other funds holding ETRM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FANJ

Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return

Glenmede Trust's ETRM Position: Q3 2017 in Review

Glenmede Trust sold out of EnteroMedics Inc. (ETRM) in Q3 2017, closing a stake of 2 shares.

Glenmede Trust first reported a position in ETRM in Q1 2017 and held it in 2 quarters. The position peaked at $0 in Q2 2017. 14 funds tracked by Wall St. Rank hold ETRM as of Q3 2017.

Glenmede Trust reported no remaining EnteroMedics Inc. position as of Q3 2017 after selling out during the quarter.
Glenmede Trust sold 2 EnteroMedics Inc. shares in Q3 2017.
Glenmede Trust first reported a position in EnteroMedics Inc. in Q1 2017 and held it in 2 quarters.
Glenmede Trust's EnteroMedics Inc. position peaked at $0 in Q2 2017.
14 funds tracked by Wall St. Rank held EnteroMedics Inc. as of Q3 2017.

Based on Glenmede Trust's 13F filing for Q3 2017, filed 14 Nov 2017.